Rajesh Krishnan - Feb 21, 2023 Form 4 Insider Report for Oncternal Therapeutics, Inc. (ONCT)

Role
Chief Technology Officer
Signature
/s/ Chase C. Leavitt, Attorney-in-fact
Stock symbol
ONCT
Transactions as of
Feb 21, 2023
Transactions value $
$0
Form type
4
Date filed
2/23/2023, 07:00 PM
Previous filing
Jan 5, 2023
Next filing
Jul 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONCT Stock Option Award $0 +220K $0.00 220K Feb 21, 2023 Common Stock 220K $0.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date.